AR070280A1 - Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) - Google Patents
Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)Info
- Publication number
- AR070280A1 AR070280A1 ARP090100267A ARP090100267A AR070280A1 AR 070280 A1 AR070280 A1 AR 070280A1 AR P090100267 A ARP090100267 A AR P090100267A AR P090100267 A ARP090100267 A AR P090100267A AR 070280 A1 AR070280 A1 AR 070280A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- antibodies
- cdmab
- monoclonal antibodies
- cancer diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método para producir anticuerpos que modifican enfermedades cancerosas. Al segregar los anticuerpos anti-cancerosos que usan citotoxicidad de células cancerosas como un punto final, el proceso hace posible la produccion de anticuerpos anti-cancerosos para fines terapéuticos y de diagnostico. Los anticuerpos se pueden usar para ayudar a determinar el estadio y diagnosticar el cáncer, y se pueden usar para tratar tumores primarios y metástasis tumorales. Los anticuerpos anti-cancerosos se pueden conjugar a toxinas, enzimas, compuestos radioactivos, y células hematogenas. Composiciones farmacéuticas, una línea celular del hibridoma depositado como IDAC 181207-01, anticuerpo humanizado o quimérico. Un ensayo de union para determinar la presencia de células cancerosas en una muestra de tejido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2405608P | 2008-01-28 | 2008-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070280A1 true AR070280A1 (es) | 2010-03-25 |
Family
ID=40899465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100267A AR070280A1 (es) | 2008-01-28 | 2009-01-28 | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090191197A1 (es) |
EP (1) | EP2238171A4 (es) |
JP (1) | JP2011511767A (es) |
AR (1) | AR070280A1 (es) |
CA (1) | CA2712535A1 (es) |
CL (1) | CL2009000175A1 (es) |
PE (1) | PE20091365A1 (es) |
TW (1) | TW200938635A (es) |
WO (1) | WO2009117804A1 (es) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
NZ222509A (en) * | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5171655A (en) * | 1989-08-03 | 1992-12-15 | Fuji Photo Film Co., Ltd. | Photohardenable light-sensitive composition |
EP0539970B1 (en) * | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
DE69432926T2 (de) * | 1993-02-05 | 2004-05-13 | Epigen, Inc., Wellesley | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
EP1018518A2 (en) * | 1994-06-24 | 2000-07-12 | Vladimir P. Torchilin | Use of autoantibodies for tumor therapy and prophylaxis |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
JP2005518393A (ja) * | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
AU2007218958A1 (en) * | 2006-02-24 | 2007-08-30 | F. Hoffmann-La Roche Ag | Cancerous disease modifying antibody 141205-02 |
US8003761B2 (en) * | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
US20080206133A1 (en) * | 2007-01-23 | 2008-08-28 | Young David S F | Cancerous Disease Modifying Antibodies |
US20080213170A1 (en) * | 2007-01-23 | 2008-09-04 | Young David S F | Cancerous Disease Modifying Antibodies |
CN101743255A (zh) * | 2007-07-16 | 2010-06-16 | 霍夫曼-拉罗奇有限公司 | 抗癌细胞毒性单克隆抗体 |
CA2692826A1 (en) * | 2007-07-16 | 2009-01-22 | F. Hoffmann-La Roche Ag | An anti-cancer cytotoxic monoclonal antibody |
-
2009
- 2009-01-21 US US12/356,980 patent/US20090191197A1/en not_active Abandoned
- 2009-01-22 EP EP09725668A patent/EP2238171A4/en not_active Withdrawn
- 2009-01-22 JP JP2010543348A patent/JP2011511767A/ja not_active Withdrawn
- 2009-01-22 WO PCT/CA2009/000060 patent/WO2009117804A1/en active Application Filing
- 2009-01-22 CA CA2712535A patent/CA2712535A1/en not_active Abandoned
- 2009-01-23 TW TW098103017A patent/TW200938635A/zh unknown
- 2009-01-28 PE PE2009000114A patent/PE20091365A1/es not_active Application Discontinuation
- 2009-01-28 AR ARP090100267A patent/AR070280A1/es unknown
- 2009-01-28 CL CL2009000175A patent/CL2009000175A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009117804A1 (en) | 2009-10-01 |
JP2011511767A (ja) | 2011-04-14 |
PE20091365A1 (es) | 2009-09-23 |
EP2238171A4 (en) | 2011-10-19 |
US20090191197A1 (en) | 2009-07-30 |
CA2712535A1 (en) | 2009-10-01 |
CL2009000175A1 (es) | 2010-02-12 |
TW200938635A (en) | 2009-09-16 |
EP2238171A1 (en) | 2010-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1718737T3 (da) | Cancerøs sygdomsmodificerende antistoffer | |
WO2007095749A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of trop-2 | |
AR077998A1 (es) | Proteinas terapeuticas de union a dll4 | |
NO20066075L (no) | Antistofflegemiddelkonjugater og fremgangsmater | |
MX2009007619A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
ECSP12012138A (es) | Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello | |
BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
MX2009001015A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
EA200601405A1 (ru) | Гуманизированное антитело | |
WO2011119888A3 (en) | N-cadherin: target for cancer diagnosis and therapy | |
MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
DK1613656T3 (da) | Cancersygdomsmodificerende antistoffer | |
WO2004065422A3 (en) | Cancerous disease modifying antibodies | |
WO2005012361A3 (en) | Antibodies raised against colon carcinomas | |
AR070279A1 (es) | Anticuerpos modificadores de enfermedades cancerosas (cdma) | |
AR070280A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) | |
MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
AR072750A1 (es) | Anticuerpos modificadores de enfermedades cancerosas | |
AR070278A1 (es) | Aislamiento y produccion de anticuerpos modificadores de enfermedades cancerosas (cdmab) y uso de los mismos | |
AR071847A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas | |
MX2009011667A (es) | Anticuerpos de modificacion de enfermedad cancerosa. | |
ATE483028T1 (de) | Antikörper, die krebserkrankungen modifizieren | |
AR071308A1 (es) | Anticuerpos monoclonales (producidos por el hibridoma idac 200208-03), que modifican enfermedades cancerosas | |
NO20091459L (no) | Cancerose sykdomsmodifiserende antistoffer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |